What is Vir Biotechnology, Inc.'s stock issuance proceeds?

Vir Biotechnology, Inc. (VIR) reported stock issuance proceeds of $162.35M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Vir Biotechnology, Inc. VIR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

Gilead SciencesGILD

$166M-34.1%

Viridian Therapeutics, Inc.VRDN

$0-100%

Iovance Biotherapeutics, Inc.IOVA

$98.51M-33.9%

Nuvation BioNUVB

$908K-16.1%

Enliven TherapeuticsELVN

$10.05M+4,196%

Other financials

Income statement

See full

Revenue-$29.0K-101%

Gross profit$1.2M-60.2%

Operating income-$132.3M+5.2%

Net income-$125.7M-3.9%

EPS (diluted)-$0.85+3.4%

Balance sheet

See full

Cash & equivalents$283.0M-23.1%

Total debt$95.6M-0.5%

Total equity$812.8M-22.1%

Total assets$1.0B-21.6%

Cash flow

See full

Operating cash flow-$132.4M-69.5%

CapEx$390.0K-76.1%

Free cash flow-$132.8M-66.5%

Valuation

See full

Market cap$1.71B+61.1%

Enterprise value$1.53B+102%

P/S26.2×-24.8×

Profitability

See full

Gross margin96.1%-2.7pp

Operating margin-720.8%-313pp

Net margin-676%-291pp

FCF margin-686.5%-273pp

Returns & leverage

See full

Return on equity-47.7%+3.6pp

Debt / equity0.1×0.0×

Current ratio7.1×+0.3×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vir Biotechnology, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vir Biotechnology, Inc.'s stock issuance proceeds?: Vir Biotechnology, Inc. (VIR) reported stock issuance proceeds of $162.35M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.